GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Price-to-Free-Cash-Flow

Genocea Biosciences (Genocea Biosciences) Price-to-Free-Cash-Flow : N/A (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Genocea Biosciences Price-to-Free-Cash-Flow?

As of today (2024-05-01), Genocea Biosciences's share price is $0.0001. Genocea Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $-0.73. Hence, Genocea Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Genocea Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:

GNCAQ's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.685
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Genocea Biosciences's Free Cash Flow per Share for the three months ended in Mar. 2022 was $-0.23. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.73.


Genocea Biosciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for Genocea Biosciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Price-to-Free-Cash-Flow Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genocea Biosciences's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Genocea Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genocea Biosciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Price-to-Free-Cash-Flow falls into.



Genocea Biosciences Price-to-Free-Cash-Flow Calculation

Genocea Biosciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.0001/-0.728
=N/A

Genocea Biosciences's Share Price of today is $0.0001.
Genocea Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Genocea Biosciences  (OTCPK:GNCAQ) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Genocea Biosciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences (Genocea Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Executives
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark director, officer: President and CEO C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber director 2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell 10 percent owner
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner officer: VP of Research C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani director 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815

Genocea Biosciences (Genocea Biosciences) Headlines

From GuruFocus

Genocea to Present at Upcoming Conferences

By Marketwired Marketwired 09-28-2021

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 06-23-2022

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 06-03-2022

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 05-24-2022

Genocea Biosciences to Host Investor Webinar

By GuruFocusNews GuruFocusNews 04-04-2022

Genocea to Present at Upcoming Scientific and Investor Conferences

By GlobeNewswire GlobeNewswire 09-08-2021